Gaviscon Advance is not sold in the United States because the product sold as “Gaviscon” in the US is a completely different formulation made by a different company, and the UK version has never been submitted for FDA approval. The two products share a brand name but work in fundamentally different ways, and the regulatory path to bring the UK version to the American market has never been pursued.
US and UK Gaviscon Are Different Products
This is the core of the confusion. The brand name “Gaviscon” is owned by different pharmaceutical companies in different countries. In the United States, Gaviscon is marketed as a traditional antacid. Its active ingredients are aluminum hydroxide and magnesium carbonate, which neutralize stomach acid the same way products like Tums or Maalox do. Alginic acid appears on the US label, but only as an inactive ingredient.
In the United Kingdom and much of Europe, Gaviscon Advance is an alginate-based therapy. Its primary active ingredient is sodium alginate at a dose of 1,000 mg per 10 ml serving. Rather than simply neutralizing acid, it works through a physical mechanism: the sodium alginate reacts with stomach acid to form a gel-like raft that floats on top of stomach contents. This raft acts as a physical barrier, sitting right at the junction between the stomach and esophagus where acid reflux originates. It essentially caps the “acid pocket” that forms after meals in the upper part of the stomach, preventing it from splashing upward.
A systematic review and meta-analysis published in Diseases of the Esophagus confirmed that alginate therapies treat reflux through this unique mechanical barrier effect rather than through chemical acid suppression. This distinction matters because it means Gaviscon Advance can help people whose reflux isn’t purely about acid volume, including those with non-acidic or weakly acidic reflux that standard antacids don’t address.
Why the FDA Hasn’t Approved It
The US Gaviscon and UK Gaviscon Advance are regulated under entirely different frameworks. In the US, over-the-counter antacids fall under an FDA monograph system that covers well-established ingredients like aluminum hydroxide and magnesium carbonate. The US version of Gaviscon fits neatly into this existing category.
Sodium alginate as a primary active ingredient for reflux treatment doesn’t have an equivalent FDA monograph. The FDA recognizes sodium alginate as a food additive (it’s classified as Generally Recognized as Safe for uses like thickening and emulsifying), but that’s a completely separate regulatory category from drug approval. To sell Gaviscon Advance in the US with sodium alginate listed as the active ingredient, the manufacturer would need to go through the FDA’s drug approval process, submitting clinical data demonstrating safety and efficacy for American regulatory standards.
This process is expensive and time-consuming. The company that holds the Gaviscon trademark in the US has no financial incentive to pursue it, since they already sell their own antacid version under that brand name. And the UK manufacturer would face both the cost of FDA approval and potential trademark conflicts. Neither party has chosen to invest in making it happen.
Health Considerations With Gaviscon Advance
Gaviscon Advance isn’t without drawbacks that could complicate US approval. According to its official UK prescribing information, each 5 ml dose contains 57.85 mg of sodium, which the product label notes is equivalent to 2.9% of the WHO’s recommended maximum daily sodium intake. The label explicitly flags this as a concern for people on low-salt diets, particularly those with congestive heart failure or kidney problems.
Each 5 ml dose also contains 39.06 mg of potassium, which needs consideration for anyone with reduced kidney function or on a controlled potassium diet. These mineral levels aren’t dangerous for most people, but they represent the kind of safety profile detail the FDA would scrutinize during any approval process, especially for a product intended for frequent OTC use.
Can You Import It for Personal Use?
Many US residents order Gaviscon Advance from UK pharmacies or through online retailers. The legal landscape here is murky. FDA policy states that importing unapproved drugs into the US is technically illegal in most circumstances. An imported drug can be refused entry if it is unapproved, if its labeling doesn’t comply with FDA regulations, or if the manufacturer isn’t registered with the FDA.
However, the FDA also has a personal importation policy that outlines situations where the agency generally does not take enforcement action. In practice, small quantities of medications ordered for personal use often pass through customs without issue, though there’s no guarantee. The FDA retains the authority to seize shipments at any time. People who import Gaviscon Advance typically order one or two bottles at a time from UK-based online pharmacies that ship internationally.
US Alternatives With Alginate
A few smaller companies have started selling alginate-based reflux products in the US market, recognizing the demand created by Gaviscon Advance’s unavailability. Products like Reflux Gourmet and Esophageal Guardian contain sodium alginate as a key ingredient and are marketed as medical foods or dietary supplements rather than OTC drugs, which allows them to sidestep the FDA drug approval process. These products aim to replicate the raft-forming mechanism that makes Gaviscon Advance effective, though their exact formulations and alginate concentrations vary.
The US version of Gaviscon does contain alginic acid, so it provides some raft-forming action. But because the alginate is listed as an inactive ingredient rather than the primary active component, the concentration is lower and the raft effect is weaker compared to Gaviscon Advance’s 1,000 mg alginate dose. For people who find that standard US antacids don’t adequately control their reflux symptoms, the alginate-forward alternatives or imported Gaviscon Advance remain the main options.